Pioglitazone Protected against Cardiac Hypertrophy via Inhibiting AKT/GSK3β and MAPK Signaling Pathways

Figure 1

PIO inhibited cardiac hypertrophy in vivo. (a) Echocardiography results of LVDD, LVEF, and LVFS of the indicated groups (–12). (b) Results of the HW/BW, HW/TL ratios of the indicated groups (–15). (c) Gross hearts, HE staining, and cross-sectional area after 8 weeks of AB or sham with or without PIO (). (d) Expression levels of the transcripts for ANP, BNP, and β-MHC normalized by GAPDH of the indicated groups (). as compared with the corresponding sham group. versus the AB group.

(a)

(b)

(c)

(d)